These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 23435403)

  • 1. Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy.
    Broge T; Nguyen N; Sacks A; Davis M
    Inflamm Bowel Dis; 2013 Apr; 19(5):E75-7. PubMed ID: 23435403
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab-induced psoriasis during therapy for Crohn's disease.
    Steinwurz F; Denadai R; Saad-Hossne R; Queiroz ML; Teixeira FV; Romiti R
    J Crohns Colitis; 2012 Jun; 6(5):610-6. PubMed ID: 22398095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First case report of adalimumab-induced psoriasis in Crohn's disease.
    Harris MD; Richards R
    Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
    [No Abstract]   [Full Text] [Related]  

  • 4. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease.
    Salgueiro P; Lago P; Pedroto I
    J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103
    [No Abstract]   [Full Text] [Related]  

  • 5. [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease].
    Avila Alvarez A; García-Alonso L; Solar Boga A; García-Silva J
    An Pediatr (Barc); 2009 Mar; 70(3):278-81. PubMed ID: 19409245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.
    Andrisani G; Marzo M; Celleno L; Guidi L; Papa A; Gasbarrini A; Armuzzi A
    Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2831-6. PubMed ID: 24174369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
    Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
    Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
    Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
    J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A; Bonnet D; Thebault S; Alric L
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
    Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi A; Elisei W; Picchio M; Penna A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
    [No Abstract]   [Full Text] [Related]  

  • 16. Guttate psoriasis induced by infliximab in a child with Crohn's disease.
    Costa-Romero M; Coto-Segura P; Suarez-Saavedra S; Ramos-Polo E; Santos-Juanes J
    Inflamm Bowel Dis; 2008 Oct; 14(10):1462-3. PubMed ID: 18383177
    [No Abstract]   [Full Text] [Related]  

  • 17. [Adalimumab in Crohn's disease - data from real life].
    López San Román A; Van Domselaar M; Garrido E
    Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
    [No Abstract]   [Full Text] [Related]  

  • 18. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab-induced psoriasis in a patient with Crohn's disease.
    Korkmaz U; Duman AE; Dindar G; Yilmaz H; Dursun IH; Celebi A; Senturk O; Hulagu S
    Indian J Gastroenterol; 2013 Mar; 32(2):135-6. PubMed ID: 23151897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.